Last Updated : April 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis | Active | |||
| N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Active | |||
| N/A | Nab-paclitaxel | Solid tumours | Active | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active | |||
| TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
| N/A | mepolizumab | Eosinophilic Granulomatosis with Polyangiitis | Active | |||
| N/A | Nab-paclitaxel | Gastrointestinal cancer | Active | |||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
| Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn |
Last Updated : April 16, 2024